By Fineline Cube 
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced plans to invest up to USD 550 million in its Diagnostics site in Indianapolis by 2030. The investment aims to establish the facility as a major hub for manufacturing Roche’s continuous glucose monitoring (CGM) systems. This initiative builds on over USD 800 million in U.S. investments made by Roche since 2015, underscoring the company’s long-term commitment to U.S. operations and the country’s pivotal role in its global strategy.
CGM Manufacturing Facility
The new CGM manufacturing facility is designed to address the growing demand from over 38 million people in the U.S. living with diabetes, providing them with effective tools for disease management. The Indianapolis campus, which encompasses U.S. research and development, laboratories, manufacturing, distribution, IT, and administrative functions, currently produces approximately 5.2 billion Accu-Chek diabetes test strips annually. It also serves as one of two global distribution hubs, focusing on serving the U.S. market and supporting distribution to 53 countries worldwide.-Fineline Info & Tech